It was Fed day today, so the market was very macro driven in terms of price action. The Bernank doubled down on easing, which was a good macro environment. That being said biotechs were more mixed. I am actually starting to look at biopharma as more QE will likely lead to yield chasing. There were […]
September 17- EOD
Not a lot of stock specific news but some interesting larger biotech developments. The market held up better than I thought given yesterday’s close and biotechs seemed like slight underperformers but not to the same degree as yesterday. That being said I think the CLVS news seemed to bring in some buyers, so they ended […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
September 16- EOD
It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]
Week’s Option Activity (9/3~9/13)
The following stocks had notable activity in their options during the past week(s): $RPRX (9/3): Several large trades today. First, 1,580 OCT 30.0 strike Calls (stock at $21.14) were bought for 1.20 or $189,600 – buyer makes money if stock trades north of $31.20 by October expiration. Second, what appears to be a SEP ratioed […]
GERN – Quick Take on Geron
Geron shares have run up substantially in recent days on speculation of positive results for its telomerase inhibitor imetelstat in an investigator sponsored study for the treatment of myelofibrosis. During the August 8th Q2 conference call, management noted the second 11 patient cohort had completed enrollment and met the pre-specified criteria of at least 2 […]
September 13- EOD
Generally a mixed day in biotech land today with some interesting stock specific moves but nothing really dramatic in terms of news. Looks like a quiet end to the week with stocks essentially performing in line with the broader market. 1. ECYT was up nicely today on the back of a Seeking Alpha article by […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 11- Morning
This is both an early and short report for today as I am on sick child duty for the day. Luckily it was not a particularly newsy morning and if there is something particularly compelling I will write a short note this evening. 1. I did want to follow up on the SGMO abstracts that […]
MYGN – To Myriad Investors – Your Risks are MyRisk
Co-Author: Dr. Tro Kalayjian Myriad (NASDAQ:MYGN) is a molecular diagnostics company that focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests in the United States. Their most well-known tests include BRACAnalysis/ BART, which are tests for hereditary breast and ovarian cancer, and COLARIS, another hereditary cancer test for colon […]
SGMO – Abstracts
The SGMO ICAAC abstracts are now available. This links to the late breaker abstract. Abstract: Background: Expression of CCR5 by CD4 cells is necessary for productive R5 HIV infection. Biallelic KO of CCR5 in CD4 cells by SB-728-T is enhanced in CCR5 Δ32HZ. This study was undertaken to assess the effect of SB-728-T on Δ32HZ, […]
September 10- EOD
Decent day in the market but biotechs did not seem to participate to the same extent. Of course, I do not have much time to follow the market on Tuesday but today seemed more like a consolidation day for biotechs than a follow through. There was a decent amount of red on my screen with […]
September 9- EOD
Some interesting news today and generally a positive market environment, although some of the recent high fliers seemed to take most of the day off. That is not completely surprising to see a pause in the moves. 1. BIOD was the stock of the weekend (and morning) given that they released what was originally argued […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
